相关实验视频
Updated: Jun 11, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
从临床开发到现实世界的结果与inclisiraniran
Derek L Connolly1,2, Vinoda Sharma1,2, Kausik K Ray3
1Department of Cardiology, Birmingham City Hospital.
新型RNA疗法Inclisiran有效降低高达52%的LDL胆固醇,每两年注射一次. 这种治疗显示出有利的安全性和持续有效性,可降低心血管风险.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 在RNA治疗方面,RNA疗法.
背景情况:
- 英克利西兰是一种小干扰RNA,准PCSK9 mRNA.
- 这种机制减少了LDL受体的降解,降低了LDL胆固醇.
- 它补充了现有的降脂疗法.
研究的目的:
- 审查关于inclisiran治疗的最新数据.
- 概述正在进行的和未来的研究.
- 评估inclisiran在脂质管理中的作用.
主要方法:
- 从inclisiran试验中发表的数据的审查 (ORION 9,10,11).
- 对接受他类药物治疗的患者的安全性和疗效的分析.
- 考虑正在进行的3b期随机对照试验.
主要成果:
- 两年一次的inclisiran注射可以将LDL胆固醇降低高达52%,而不是安慰剂.
- 全球范围内注射了50多万剂,没有显著的不良事件.
- 在3a期试验中观察到持续有效性长达7年.
结论:
- 英克利西兰在轻微的,短暂的注射部位反应中表现出良好的安全性.
- 每年两次的剂量提供了一个用户友好的给药时间表.
- 恩克利西兰是治疗失脂症管理的治疗选择中一个有价值的补充.
更多相关视频
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
相关概念视频
Clinical Trials: Overview
Preclinical Development: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...